

HOW TO REDUCE VISCERAL FAT AND DECREASE HUNGER

BY XANYA SOFRA, PH.D



身体活动增加：
心血管健康
肌肉量
健康的血糖调节
减少内脏脂肪
甘油三酯
低密度脂蛋白。

VS

久坐的生活方式促进：

- 脂肪组织堆积
- * 全身炎症
- 氧化损伤
- 慢性疼痛



疾病





运动需求 承诺 时间 活力 耐力 持久性



运动不关心
时间限制
职业责任
肥胖导致行动受限
慢性疼痛
个人选择




全球超过
10 亿人肥
胖



肥胖 胰岛素抵抗 1. 2 型糖尿病 2. 高血压 3. 心血管疾病 (CVD)







16 分钟的低强度激光治疗 (LLLT) 结合 1 小时的有氧和阻力运动，通过电导量表测量报告了内脏脂肪减少。然而，目前尚不清楚结果是由于 LLLT 还是演习

同一研究人员的后续研究表明，实验组和对照组之间的内脏脂肪没有差异 无外部有效性

Duarte, F., Seme-Fiorese, M., Eduard de Aquino, A., Campos, R., Masquio, D., Tock, L., Duarte, A., Bagnato, V., Parizotto, N. (2018). The Effects of Exercise Training Associated With Low-Level Laser Therapy on Biomarkers of Adipose Tissue Transdifferentiation in Obese Women. *Lasers Med Sci.* 33(6):1245-1254. doi: 10.1007/s10103-018-2465-1. Epub 2018 Feb 23. PMID: 29473115

没有关于内脏脂肪减少的同行评审 RF 研究

锻炼的局限性



随机安慰剂对照数据显示，经过 8 周的有氧运动，内脏脂肪组织略有减少，脂肪肝得到改善

阻力训练导致低密度脂蛋白 (LDL) 水平显著降低，肌肉力量得到改善，但 BMI 没有差异

运动平衡荷尔蒙



年轻**健康**时**轻松**锻炼



当你积累了体重并不那么容易

50岁以上的健身房锻炼




你不会得到这个! ↑



你会得到这个! ↑

摆脱内脏脂肪需要非常剧烈的运动

过度训练会破坏 PH 平衡



乳酸





乳酸性酸中毒会破坏身体的 pH 平衡

摆脱内脏脂肪需要非常剧烈的运动


过度训练会导致更大的激素失衡

Testosterone & Cortisol - their inverse balance




皮质醇

睾酮





Benefits of Optimal Testosterone



这就是为什么我们需要虚拟健身房

皮质醇增多症

Symptoms





虚拟健身房与电动肌肉刺激器 EMS 或电磁设备有何不同？



虚拟健身房向大脑发送信号，大脑命令运动神经收缩整个身体，从而像在各种运动中一样进行整整 10 秒的收缩 因此，荷尔蒙、能量、最佳免疫力和全身平衡都会增加。 虚拟健身房提供身体调整

VS



肌肉刺激和电磁装置每秒发送多个脉冲，仅直接在刺激区域下刺激单个肌肉，它们不涉及大脑

Table 1. Blood Plasma Subjects Results on Testosterone and Cortisol for each subject.

VIRTUAL GYM RESULTS

Gender	Age	Ethnicity	Testosterone Pre (nmol/l)	Testosterone post (nmol/l)	Normal range (nmol/l)	Testosterone % increase	Cortisol pre (nmol/l)	Cortisol post (nmol/l)	Normal range (nmol/l)	Cortisol% decrease
Male	36	Asian	14.75	17.3	8.64 - 29	17.28%	158	121	80 - 477.3	-23.42%
Male	39	Caucasian	11.34	13.96	8.64 - 29	23.1%	182	144	80 - 477.3	-20.87%
Male	43	Caucasian	12.38	14.6	8.64 - 29	17.92%	219	198	80 - 477.3	-9.6%
Male	35	Asian	15.41	18.65	8.64 - 29	21.02%	143	138	80 - 477.3	-3.49%
Female	42	Asian	0.5	0.92	0.29 - 1.6	84%	185	162	80 - 477.3	-12.43%
Female	45	Indian	0.3	0.63	0.29 - 1.6	110%	198	183	80 - 477.3	-7.6%
Female	49	Caucasian	0.72	1.01	0.29 - 1.6	52.77%	129	112	80 - 477.3	-13.18%
Female	38	Caucasian	0.63	0.78	0.29 - 1.6	23.8%	173	129	80 - 477.3	-25.43%
Female	37	Asian	0.53	0.69	0.29 - 1.6	30.18%	256	231	80 - 477.3	-49.76%
Mean Average Testosterone % Increase 睾酮						+42.23%	Mean Average Cortisol % Decrease 皮质醇			-18.42%

Both testosterone increase and cortisol decrease remained within the normal range. Testosterone overall increase was +42.23%. Testosterone showed a mean average increase of +20.15% increase for males and a mean average of +60.15% for females. Cortisol showed a mean average decrease of -18.42%.

Mean Average Testosterone
% Increase


睾酮

62.18
%

Mean Average 皮质醇
Cortisol % Decrease

7.33
%


GENDER	TESTOSTERONE PRE	TESTOSTERONE POST	Normal Range (nmol/L)	% Increase	CORTISOL PRE	CORTISOL POST	Normal Range (nmol/L)	% decrease
MALE	10.92	14.6	8.64-29	33.6%	198	181	80-477.3	8.5%
MALE	12.16	15.43	8.64-29	26.9%	177	163	80-477.3	7.9%
FEMALE	0.3	0.71	0.29-1.6	136.6%	135	128	80-477.3	5.2%
FEMALE	0.4	0.9	0.29-1.6	125%	168	153	80-477.3	8.9%
MALE	15.38	21.6	8.64-29	40.4%	229	198	80-477.3	13.5%
MALE	13.41	19.92	8.64-29	48.5%	160	149	80-477.3	6.8%
FEMALE	0.64	0.92	0.29-1.6	43.7%	116	109	80-477.3	6.4%
FEMALE	0.4	0.71	0.29-1.6	77.5%	87	82	80-477.3	5.7%
MALE	11.3	14.4	8.64-29	27.4%	221	214	80-477.3	3.1%
FEMALE	0.43	0.72	0.29-1.6	67.4%	197	189	80-477.3	4%



TESTOSTERONE



CORTISOL



皮质醇

Table 5. Free T3 (triiodothyronine) and CRP (C-Reactive Protein)

Free T3 Normal Range: 2:30-4.20 pg/mL. CRP Normal Range <1 mg/dL

Subject NO from Table 1 DIABETES	Gender	Age	Medical Condition	Free T3 PRE pg/mL	Free T3 POST pg/mL	Free T3 Normal Range pg/mL	CRP PRE mg/dL	CRP POST mg/dL	Normal Range mg/dL
12	Male	46y	Diabetes	1.99	2.69	2.30-4.20	1.45	1.05	<1.00
13	Male	59y	Diabetes	1.92	2.78	2.30-4.20	1.29	1.08	<1.00
14	Female	45y	Diabetes Fatty Liver	2.12	2.55	2.30-4.20	2.51	1.25	<1.00
15	Male	59y	Diabetes	1.97	2.62	2.30-4.20	1.83	0.96	<1.00
16	Male	49y	Diabetes	1.18	2.29	2.30-4.20	1.13	0.91	<1.00
17	Female	69y	Diabetes Fatty Liver	1.43	2.42	2.30-4.20	1.67	1.01	<1.00
18	Female	53y	Diabetes	1.63	2.15	2.30-4.20	1.09	0.86	<1.00
19	Female	68y	Diabetes Fatty Liver	1.93	2.88	2.30-4.20	1.18	0.84	<1.00
20	Female	61y	Diabetes Fatty Liver	2.23	2.37	2.30-4.20	1.94	0.95	<1.00
21	Male	55y	Diabetes	1.47	2.26	2.30-4.20	2.23	1.03	<1.00
Subject NO from Table 2 PREDIABETES									
14	Female	33	Prediabetes	2.25	2.77	2.30-4.20	1.09	0.76	<1.00
15	Male	49y	Prediabetes	2.22	2.58	2.30-4.20	1.59	1.05	<1.00
16	Male	69y	Prediabetes	1.68	2.51	2.30-4.20	1.19	1.02	<1.00
17	Male	53y	Prediabetes	1.99	2.89	2.30-4.20	2.42	1.25	<1.00
18	Female	68y	Prediabetes	1.28	2.25	2.30-4.20	1.98	0.99	<1.00
19	Female	49y	Prediabetes	1.43	2.36	2.30-4.20	1.52	1.14	<1.00
20	Female	52y	Prediabetes	1.53	2.14	2.30-4.20	1.75	1.03	<1.00
14	Female	33	Prediabetes	1.97	2.78	2.30-4.20	1.08	0.89	<1.00
				32.22	45.29		28.94	18.07	
Average Free T3 Pre & Post				1.79 BELOW Normal	2.52 Normal	Average CRP Pre & Post	1.61 BELOW Normal	1.00 Improved	
Free T3 Percentage Increase					+40.78%	Average CRP Percentage Decrease		-37.88%	

骨骼肌增加

SKELETAL MUSCLE MASS (SMM) INCREASE

Mean Average % Increase for Skeletal Muscle mass **36.45%**

GENDER	SKELETAL MUSCLE MASS PRE	SKELETAL MUSCLE MASS POST	SKELETAL MUSCLE MASS (SMM) % Increase
MALE	36.40	43.80	20.3%
MALE	30.30	38.60	27.39%
FEMALE	18.40	27.00	46.79%
FEMALE	17.00	26.80	57.64%
MALE	37.80	44.80	18.5%
MALE	29.40	38.30	30.27%
FEMALE	17.20	26.80	55.81%
FEMALE	19.80	28.80	45.45%
MALE	29.80	37.22	25.89%
FEMALE	17.95	26.63	48.35%




IGF-I INCREASE

Mean Average IGF-1 % Increase. IGF-I 增加

25.85% WITHIN THE NORMAL RANGE

GENDER	IGF-1 PRE	IGF-1 POST	Normal Range (nmol/L)	IGF-1% Increase
MALE	25.97	30.35	15.08-32.5	16.86%
MALE	23.98	31.12	15.08-32.5	29.77%
FEMALE	16.33	20.75	11.25-28.8	27.06%
FEMALE	15.14	19.21	11.25-28.8	26.88%
MALE	22.27	28.11	15.08-32.5	26.22%
MALE	26.98	30.52	15.08-32.5	11.80%
FEMALE	15.86	21.08	11.25-28.8	32.91%
FEMALE	18.55	23.50	11.25-28.8	26.68%
MALE	24.56	31.34	15.08-32.5	27.60%
FEMALE	19.34	25.66	11.25-28.8	32.67%







甘油三酯



激光和射频脂肪分解将甘油三酯、葡萄糖和毒素释放到血液中。一个健康的肝脏会处理这个问题。但是排毒会是个问题 患有脂肪肝的人



没有运动，甘油三酯和毒素会留在血液中，使脂肪过多，并可能阻塞动脉这就是为什么虚拟健身房可以提供帮助

Mean Average Triglycerides Decrease

甘油三酯减少

40.7%

GENDER	TRIGLYCERIDES PRE	TRIGLYCERIDES POST	Normal Range (nmol/L)	TRIGLYCERIDES % Decrease
MALE	2.90	1.23	<1.7	55%
MALE	2.34	0.94	<1.7	59.8%
FEMALE	2.50	1.50	<1.7	40%
FEMALE	2.00	1.44	<1.7	28%
MALE	0.80	0.53	<1.7	33%
MALE	0.90	0.64	<1.7	41.1%
FEMALE	1.00	0.60	<1.7	40%
FEMALE	0.90	0.58	<1.7	35%
MALE	1.32	0.92	<1.7	30%
FEMALE	0.98	0.54	<1.7	44.9%



VLDL (THE BAD CHOLESTEROL) DECREASE

胆固醇降低

Mean Average VLDL Decrease					71.88%
GENDER		VLDL PRE	VLDL POST	Normal Range (nmol/L)	VLDL CHOLESTEROL % Decrease
MALE		1.48	0.24	<1.6	83.78%
MALE		1.55	0.64	<1.6	58.7%
FEMALE		0.80	0.20	<1.6	75%
FEMALE		0.86	0.27	<1.6	68.6%
MALE		0.52	0.04	<1.6	92.3%
MALE		1.36	0.24	<1.6	82.35%
FEMALE		0.68	0.05	<1.6	92.64%
FEMALE		0.53	0.26	<1.6	50.9%
MALE		1.53	0.67	<1.6	56.20%
FEMALE		1.75	0.73	<1.6	58.28%



Table 4. PREDIABETICS
Triglycerides, High-Density Protein (HDL),
Presence of Fatty Liver on Sonography Reports Pre and Post Treatment.

Triglycerides Normal Range: > 150 mg/dL;
 High-Density Lipoprotein (HDL) Normal Range: Men >60 mg/dL; Women >60 mg/dL

High-Density Lipoprotein (HDL) At Risk: Men: < 40 mg/dL; Women < 50 mg/dL

No	Gender	Age	Medical Diagnosis Pre Treatment	Triglycerides mg/dL Pre	Triglycerides mg/dL Post	Triglycerides mg/dL decrease	HDL mg/dL Pre	HDL mg/dL Post	HDL mg/dL Increase
1	Female	43y	Prediabetes	294	197	Improved (abnormal)	36	42	At risk
2	Female	27y	Prediabetes	192	126	Normal	36	48	At risk
3	Female	63y	Prediabetes	155	117	Normal	45	47	At risk
4	Female	24y	Prediabetes	88	86	Normal	45	52	Normal
5	Female	30y	Prediabetes	156	124	Normal	37	46	At risk
6	Male	15y	Prediabetes	187	132	Normal	36	42	Normal
7	Male	58y	Prediabetes	141	136	Normal	39.1	46.8	Normal
8	Male	46y	Prediabetes	262	158	Improved (abnormal)	34.3	56	Normal
9	Female	24y	Prediabetes	186	148	Normal	41	58	Normal
10	Male	40y	Prediabetes	178	137.6	Normal	34.8	45.4	Normal
11	Male	50y	Prediabetes	169	142.8	Normal	34.7	43.0	Normal
12	Male	39y	Prediabetes	172	139.2	Normal	29.6	48.8	Normal
13	Male	31y	Prediabetes	159	122.4	Normal	26.6	53.4	Normal
14	Female	33	Prediabetes	163.6	134.8	Normal	39.3	67.2	Normal
15	Male	49y	Prediabetes	158.9	128.3	Normal	34.7	53.1	Normal
16	Male	69y	Prediabetes	184.6	148.9	Normal	29.4	54	Normal
17	Male	53y	Prediabetes	176	146.8	Normal	39.2	51.6	Normal
18	Female	68y	Prediabetes	154.7	129.6	Normal	47.2	58.5	Normal
19	Female	49y	Prediabetes	154.6	121.7	Normal	47.4	52.5	Normal
20	Female	52y	Prediabetes	189	138.5	Normal	46.2	57.9	Normal
TOTAL				3520.4	2714.6		785.5	1023.2	
AVERAGE				176.02	135.73		39.25	51.16	
HIGH					Normal		LOW	Normal	
甘油三酯降低				Average decrease in Triglycerides		-22.88	Average Increase in HDL		30.34

高密度脂蛋白增加


Fasting Blood Glucose: Normal <100 mg/dL; Prediabetes = 100 - 125 mg/dL; Diabetes >126mg/dL Blood Glucose Postprandial (PP): Normal < 140 mg/dL; Prediabetes = 140 - 199 mg/dL; Diabetes > 199 mg/dL									
S	G	A	Medical Diagnosis Post Tx	Blood Glucose Fasting mg./dL Pre Tx	Blood Glucose Fasting mg/dL Post Tx	Blood Glucose Normal <100 mg/dL Post Tx	Blood Glucose PP mg/dL Pre Tx	Blood Glucose PP mg/dL Post Tx	Blood Glucose PP Normal < 140 mg/dL Post Tx
1	F	45	Diabetes Fatty liver	178	104	Prediabetic	260	185	Prediabetic
2	M	69	Diabetes	209	108	Prediabetic	230	125	Normal
3	M	46	Diabetes	131.7	99.15	Normal	290	183.2	Prediabetic
4	F	50	Diabetes	177	106	Prediabetic	221	176	Prediabetic
5	F	49	Diabetes Fatty Liver	192	102	Prediabetic	248	175	Prediabetic
6	F	48	Diabetes Fatty Liver	189	115	Prediabetic	224	163	Prediabetic
7	M	44	Diabetes Fatty Liver	178	109	Prediabetic	196	162	Prediabetic
8	F	45	Diabetes Fatty Liver	186	117	Prediabetic	197	126	Normal
9	F	47	Diabetes Fatty Liver	169	102	Prediabetic	243	178	Prediabetic
10	M	45	Diabetes	135	92	Normal	218	156	Prediabetic
11	M	82	Diabetes	136	87	Normal	191	142	Prediabetic
12	M	46	Diabetes	134	97	Normal	216.3	139	Normal
13	M	59	Diabetes	106.8	82	Normal	199.9	133	Normal
14	F	45	Diabetes Fatty Liver	186	117	Prediabetic	207.5	123	Normal
15	M	59	Diabetes	188	119	Prediabetic	202	133	Prediabetic
16	M	49	Diabetes	141	99	Normal	125.6	144	Prediabetic
17	F	69	Diabetes Fatty Liver	136	87	Normal	231.4	131	Normal
18	F	53	Diabetes	190	108.5	Prediabetic	212	118	Normal
19	F	68	Diabetes Fatty Liver	176	92	Normal	209.8	98	Normal
20	F	61	Diabetes Fatty Liver	157.5	98.5	Normal	204	103	Normal
21	M	55	Diabetes Fatty Liver	194	107	Prediabetic	231	138	Normal
Total				3490	2148..15		4557.5	3031.2	
Average				166.19	102.29	Normal	237.02	144.34	Normal
Percentage Of Blood Glucose Decrease				Blood Fasting Glucose % Decrease	-38.44%		Blood PP Glucose % Decrease	-39.1%	
糖尿病患者血糖下降									

Table 2 PREDIABETICS
Pre and Post Treatment Results on Insulin (Fasting and PP)

No	Gender	Age	Medical Diagnosis	Insulin Fasting: Normal < 25 mIU/ml		Insulin Postprandial (PP): Normal <75			
				Insulin Fasting mIU/ml Pre	Insulin Fasting mIU/ml Post	Insulin Fasting Normal < 25 mIU/ml	Insulin PP mIU/ml Pre	Insulin PP mIU/ml Post	Insulin PP Normal <75 mIU/ml
1	Female	43y	Prediabetes	72	15.7	Normal	174.3	73.9	Normal
2	Female	27y	Prediabetes	25.8	8.7	Normal	136	74	Normal
3	Female	63y	Prediabetes	105	12.27	Normal	150	76.2	Normal
4	Female	24y	Prediabetes	34	21	Normal	139.9	71.8	Normal
5	Female	30y	Prediabetes	27.4	18.5	Normal	241	24.6	Normal
6	Male	15y	Prediabetes	29	10.9	Normal	136.6	74.8	Normal
7	Male	58y	Prediabetes	50.4	24	Normal	246	68.4	Normal
8	Male	46y	Prediabetes	25.56	12.56	Normal	68.8	23.5	Normal
9	Female	39y	Prediabetes	48	24.9	Normal	69.7	72	Normal
10	Male	40y	Prediabetes	22.2	11.8	Normal	127.2	73.4	Normal
11	Male	53y	Prediabetes	23.8	14.6	Normal	102.8	96.8	Prediabetes
12	Male	39y	Prediabetes	19.5	14.6	Normal	103.9	68.8	Normal
13	Male	31y	Prediabetes	43.5	22.8	Normal	116.3	73.4	Normal
14	Female	33	Prediabetes	41.9	18.6	Normal	109.3	68.4	Normal
15	Male	49y	Prediabetes	53.7	24.8	Normal	126.4	73.8	Normal
16	Male	69y	Prediabetes	35.8	27.4	Prediabetic	112.4	83.74	Prediabetic
17	Male	53y	Prediabetes	42.7	23.12	Normal	93.4	71.6	Normal
18	Female	68y	Prediabetes	53.6	28.9	Prediabetic	77.2	70.65	Normal
19	Female	49y	Prediabetes	42.8	23.4	Normal	81.4	72.5	Normal
20	Female	52y	Prediabetes	39.8	21.7	Normal	76.8	64.3	Normal
TOTAL				836.46	380.25		2489.4	1376.59	
AVERAGE				41.823	19.02	NORMAL	124.47	68.83	NORMAL
PERCENTAGE OF INSULIN DECREASE				FASTING INSULIN % DECREASE	-54.52%		PP INSULIN % DECREASE	-44.7%	

糖尿病前期胰岛素降低

为什么内脏脂肪是个问题？炎症和毒性



Ferrucci L., Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nature Reviews*. 2018 *Cardiology* volume 15, pages505–522(2018). <https://www.nature.com/articles/s41569-018-0064-2>. DOI <https://doi.org/10.1038/s41569-018-0064-2>

J S Yudkin, C D Stehouwer, J J Emeis, S W Coppack. C-reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue? *Arteriosclerosis Thromb Vasc Biol*. 1999 Apr;19(4):972-8. doi: 10.1161/01.atv.19.4.972

Alexopoulos N., Katritsis D, Raggi P. 2014. Visceral Adipose Tissue as a source of inflammation and promoter of atherosclerosis. *Volume 233, Issue 1*, Pages 104-112. <https://doi.org/10.1016/j.atherosclerosis.2013.12.023>

Wener, MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. *J Rheumatol* 2000; 27:2351-9. <https://pubmed.ncbi.nlm.nih.gov/11036829/> PMID: 11036829

Skouby S., Gram J., Andersen L., Sidelmann J., Petersen K., Jespersen J., Hormone replacement therapy: Estrogen and progestin effects on plasma C-reactive protein concentrations. *American Journal of Obstetrics and Gynecology*. 2002 *Volume 186, Issue 5*, Pages 969-977. <https://doi.org/10.1067/mob.2002.122414>


Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW, Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. *J Clin Invest*. 2006; 116:115-124. <https://pubmed.ncbi.nlm.nih.gov/16341265/> DOI: [10.1172/JCI24335](https://doi.org/10.1172/JCI24335)

Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest*. 2003; 112:1821-1830. <https://pubmed.ncbi.nlm.nih.gov/14679177/> DOI: [10.1172/JCI19451](https://doi.org/10.1172/JCI19451)


Byrne C.D. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. *Proc Nutr. Soc*. 2013;72:412-419. doi: 10.1017/S0029665113001249. PMID: **23668723** DOI: [10.1017/S0029665113001249](https://doi.org/10.1017/S0029665113001249)

Marz W., Scharnagl H., Winkler K., Tiran A., Nauck M., Boehm B., Windelmann B. Low-Density Lipoprotein Triglycerides associated with Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease. *Circulation* 2004. 110: 3068-3074. <https://doi.org/10.1161/01.CIR.0000146898.06923.80>

Excess adiposity




Dyslipidemia



Hormonal imbalance

Insulin Resistance



Inflammation




TABLE 6

Pre and Post Treatment Results on BMI, Overall Fat, Visceral Fat, and Skeletal Muscle Mass (SMM)

S #	Gender	Age	MEDICAL CONDITION	BMI Pre	BMI Post	Overall Fat Pre	Overall Fat Post	Visceral Fat Pre	Visceral Fat Post	SMM Pre	SMM Post
1	Female	46	Diabetes Fatty Liver	39.2	36.2	44.6	36.8	35	24.8	22.1	29.4
2	Female	48	Diabetes Fatty Liver	41.2	38.5	42.9	33.5	33	29	23.8	29.7
3	Male	44	Diabetes Fatty Liver	42.6	38.2	34.9	24.6	29	26	34.5	47.3
4	Female	48	Diabetes Fatty Liver	32.0	30.1	42.9	33.5	29	24	23.8	31.8
5	Female	45	Diabetes Fatty Liver	29.1	25.1	34	28.7	31	27	20.7	26.3
6	Female	24	Prediabetes	29.3	25.0	34.7	33	9.5	5	21.8	24.2
7	Male	40	Prediabetes	33.7	25.1	33.0	13.4	21	13.4	28.8	31.2
8	Male	39	Prediabetes	36.2	32.0	41.1	37.4	18	14.5	36	38.9
9	Male	31	Prediabetes	43.8	39.1	37.6	34.6	30	25	25.2	27.4
10	Male	46	Diabetes	39.2	24.6	42.3	25.6	24.7	10.8	28.9	39.4
11	Male	59	Diabetes	36.5	28.9	37.9	31.6	32.3	16.4	26	41
12	Female	45	Diabetes Fatty Liver	41.3	27.4	43.8	22.7	39.5	19.4	23.8	38.5
13	Male	59	Diabetes	34.2	24.8	36.9	25.8	35.4	22.8	28.9	41.2
14	Male	49	Diabetes	37.4	29.5	41.3	22.5	29.3	18.3	35.7	42.6
15	Female	69	Diabetes Fatty Liver	42.6	36.8	44.2	37.9	34.6	31.7	27.9	33.2
16	Female	53	Diabetes	33.5	25.1	30.1	25.7	38.2	30.1	32.4	39.9
17	Female	68	Diabetes Fatty Liver	40.7	36.1	42.3	39.8	37.4	33.8	30.2	39.7
18	Female	61	Diabetes Fatty Liver	34.2	25.3	36.7	33.2	38	36.1	23.8	28.6
19	Male	55	Diabetes	36.7	26.4	38.7	29.6	33.5	23.2	27.9	39.4
20	Female	33	Prediabetes	36.8	22.5	39.2	21.3	25.3	9.4	32.5	43.2
21	Male	49	Prediabetes	35.9	24.6	39.4	18.4	24.3	8.5	35.4	48.3
22	Male	69	Prediabetes	38.2	33.7	39.6	31.5	28.3	24.6	31.4	37.8
23	Male	53	Prediabetes	37.2	30.3	40.2	29.3	36.2	30.6	29.3	36.7
24	Female	68	Prediabetes	35.7	29.4	33.6	31.4	37.3	32.9	30.8	34.2
25	Female	49	Prediabetes	35.3	25.4	37.4	21.5	27.6	10.8	38.9	47.2
26	Female	52	Prediabetes	36.1	29.6	36.5	28.3	29.7	25.3	37.5	41.3
27	Female	37	Prediabetes	39.2	23.9	47.3	24.1	28.4	12.3	24.6	42.8
TOTAL				997.8	793.6	1013.5	775.7	815.5	585.7	782.6	1001.2
MEAN AVERAGE				36.9	29.4	38.9	28.73	30.20	21.69	28.98	37.1
MEAN OVERALL BMI DECREASE: -7.5					MEAN AVERAGE OVERALL FAT DECREASE % -26.14%		MEAN VISCERAL FAT DECREASE % -28.17% 内脏脂肪减少		肌肉量增加 MEAN SMM % INCREASE +28.02%		

Table 2. Blood Test Results on C-reactive protein (CRP) and Cortisol CRP: <1.0 mg/dL. Low cardiovascular risk according to AHA/CDC CRP: 1.0-3.0 mg/dL Average cardiovascular risk according to AHA/CDC CRP:>3.0-10.0 mg/dL High cardiovascular risk according to AHA/CDC

Gender	Age	Medical History	BMI	CRP		Normal Range mg/dL	Cortisol Total, Serum ug/dL, PRE	Cortisol Total, Serum ug/dL, POST	Normal Range ug/dL
				PRE mg/dL	POST mg/dL				
Female	56	Diabetes Fatty Liver	32.6	1.56	1.02	<1.00	18.44	15.66	3.09-25.0
Female	52	Prediabetes Fatty Liver	36.5	1.09	1.06	<1.00	21.89	20.12	3.09-25.0
Female	49	Hypertension Hypothyroidism	28.6	2.31	1.15	<1.00	24.98	18.47	3.09-25.0
Female	63	Hypertension Fatty Liver	34.9	1.93	1.06	<1.00	23.43	21.98	3.09-25.0
Female	51	Prediabetes Hypertension Hypothyroidism	34.2	1.43	1.22	<1.00	18.4	15.34	3.09-25.0
Female	55	Prediabetes Fatty Liver Hypothyroidism	35.4	1.64	1.01	<1.00	19.33	14.75	3.09-25.0
Female	48	Prediabetes Fatty Liver Hypothyroidism	30.9	1.04	0.86	<1.00	9.67	8.23	3.09-25.0
Female	61	Hypertension Fatty Liver	32.7	1.08	0.74	<1.00	14.76	10.65	3.09-25.0
Female	46	Heart Disease	29.5	1.84	0.98	<1.00	17.22	13.95	3.09-25.0
Female	58	Prediabetes Fatty Liver Hypothyroidism	33.8	2.11	1.03	<1.00	21.28	17.24	3.09-25.0
MEAN TOTAL				1.60 mg/dL	1.01 mg/dL		18.95 ug/dL	15.64 ug/dL	

Mean Average CRP % Decrease. -36.87 mg/dL.

炎症减少

皮质醇减少

Mean Average Cortisol %Decrease. -17.47% mg/dL

Table 3. Blood Test Results on Creatinine and Bilirubin



Gender/ Age	BMI	Medical History	Creatinine Serum PRE mg/dL	Creatinine Serum POST mg/dL	Creatinine Normal Range mg/dL	Bilirubin mg/dL PRE	Bilirubin mg/dL POST	Bilirubin Normal Range mg/dL
F/56	32.6	Diabetes Fatty Liver	1.15	0.94	0.5-1.10	1.31	1.09	0.3-1.2
F/52	36.5	Prediabetes Fatty Liver	1.03	0.87	0.5-1.10	1.44	1.63	0.3-1.2
F/49	28.6	Hypertension Hypothyroidism	1.37	1.05	0.5-1.10	1.27	1.15	0.3-1.2
F/63	34.9	Hypertension Fatty Liver	1.23	0.96	0.5-1.10	1.35	1.18	0.3-1.2
F/51	34.2	Prediabetes Hypertension Hypothyroidism	1.14	1.02	0.5-1.10	1.18	1.08	0.3-1.2
F/55	35.4	Prediabetes Fatty Liver Hypothyroidism	1.04	1.01	0.5-1.10	1.26	1.16	0.3-1.2
F/48	30.9	Prediabetes Fatty Liver Hypothyroidism	0.97	0.82	0.5-1.10	1.23	1.13	0.3-1.2
F/61	32.7	Hypertension Fatty Liver	1.18	0.98	0.5-1.10	1.33	1.05	0.3-1.2
F/46	29.5	Heart Disease	1.11	0.87	0.5-1.10	1.22	1.07	0.3-1.2
F/58	33.8	Prediabetes Fatty Liver Hypothyroidism	1.96	1.23	0.5-1.10	1.28	1.19	0.3-1.2

Mean Average 肌酐 % 減少. -19.67 mg/dL. (exits the body as a waste product)

Mean Average. 胆红素. %. 減少. -8.85 mg/dL (excess may indicate jaundice)




Virtual Gym One Treatment




SIX TREATMENTS

Diabetic Patient with back Pain and Fatty Liver. Measures: Sonogram, Blood Test, Measuring tape, Tanita Scale, Self Reports



BEFORE	AFTER
Real Age: 43 y.o. female	METABOLIC AGE 32
Severe Obesity FAT 36.5 %	FAT% 25.8
Diabetic Status: On Insulin HbA1c- 10.8	On Oral Drugs HbA1c – 7.8
Visceral Fat Evidence Sonography Reports: Fatty Liver	NO FATTY LIVER
Lower Back Pain	NO BACK PAIN
Weight: 92.2 Kg	Significant Weight Loss 83.7 KG
Measurement: Umbilicus: 111cm	Significant Improvement: 100cm
Measurement: Lower Abdomen: 115cm	Significant Improvement: 100cm



Before



After 15 Treatments

49 Year old Patient suffering from Insulin Resistance and Diabetes. Measures: Sonogram, Tanita scale, Blood Test, Measuring Tape, Self Reports


	Before treatment	After treatment
Weight (kg)	75.8	67.2
Fat %	36.5	25.8
Upper abdomen(cm)	97	82
Umbilicus (cm)	100	88
Lower abdomen (cm)	105	94
Insulin-Fasting(miU/ml)	25.8	8.7
Insulin PP (miU/ml)	136	14
Triglycerides (mg/dl)	294	197
HDL(mg/dl) good cholesterol	36	42
Back pain	Lower Back pain +++	Significant decrease in back pain




虚拟健身房平衡
荷尔蒙

虚拟健身房
提高免疫力

VAT



SARS-CoV & SARS-CoV-2



内脏脂肪含量较高的表达 ACE2受体





肌肉的 ACE2 受体最少。
COVID-19 不容易传播

I型干扰素和免疫 干扰素反应较强的个体的 COVID-19 症状较轻

nature immunology

Explore content ▾ About the journal ▾ Publish with us ▾

nature > nature immunology > letters > article

Letter | Published: 04 December 2020

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

Ioanna Evidokia Galani, Nicoletta Rovina, Yicky Lampropoulos, Yasiliki Triantafyllis, Maria Manioudaki, Eleftherios Pavlos, Evangelia Koukaki, Paraskevi G. Fragkou, Yasiliki Panos, Yasiliki Rapti, Gurania Koftida, Andreas Mentis, Nikolaos Koulouris, Sotirios Tsioltras, Antonia Koutsoukou & Evangelos Andreoukos ^{1,2}

Nature Immunology 22, 32–40 (2021) | Cite this article
21k Accesses | 181 Citations | 95 Altmetric | Metrics

Abstract

A central paradigm of immunity is that interferon (IFN)-mediated antiviral responses precede pro-inflammatory ones, optimizing host protection and minimizing collateral damage^{1,2}. Here, we report that for coronavirus disease 2019 (COVID-19) this paradigm does not apply. By investigating temporal IFN and inflammatory cytokine patterns in 32 moderate-to-severe patients with COVID-19 hospitalized for pneumonia and longitudinally followed for the development of respiratory failure and death, we reveal that IFN- λ and type I IFN production were both diminished and delayed, induced only in a fraction of patients as they became critically ill. On the contrary, pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-6 and IL-8 were produced before IFNs in all patients and persisted for a prolonged time. This condition was reflected in blood transcriptomes wherein prominent IFN signatures were only seen in critically ill patients who also exhibited augmented inflammation. By comparison, in 16 patients with influenza (flu) hospitalized for pneumonia with similar clinicopathological characteristics to those of COVID-19 and 24 nonhospitalized patients with flu with milder symptoms, IFN- λ and type I IFN were robustly induced earlier, at higher levels and independently of disease severity, whereas pro-inflammatory cytokines were only acutely produced. Notably, higher IFN- λ concentrations in patients with COVID-19 correlated with lower viral load in bronchial aspirates and faster viral clearance and a higher IFN- λ to type I IFN ratio correlated with improved outcome for critically ill patients. Moreover, altered cytokine patterns in patients with COVID-19 correlated with longer hospitalization and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19, contributing to persistent viral presence, hyperinflammation and respiratory failure.

Share Cite

<https://doi.org/10.1016/j.intimp.2020.106924>

Get rights and content

Highlights

- **Immunotherapy**, as a viable approach to curtail COVID-19, could be done through:
- **Active immunization** by vaccines or direct **interferon** administration;
- **Passive immunization** by convalescent plasma or synthesized antibodies;
- **Immunomodulatory drugs** such as **JAK inhibitors** and **corticosteroids**.
- Immunotherapy should be adapted to the patient condition and disease stage.

Abstract

COVID-19, the disease induced by the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed an unpredictable burden on the world. Drug repurposing has been employed to rapidly find a cure; but despite great efforts, no drug or vaccine is presently available for treating or prevention of COVID-19. Apart from antivirals, immunotherapeutic strategies are suggested considering the role of the immune response as the host defense against the virus, and the fact that SARS-CoV-2 suppresses interferon induction as an immune evasion strategy. Active immunization through vaccines, interferon administration, passive immunotherapy by convalescent plasma or synthesized monoclonal and polyclonal antibodies, as well as immunomodulatory drugs, are different immunotherapeutic approaches that will be mentioned in this review. The focus would be on passive immunotherapeutic interventions.

Interferons might be helpful in some stages. Vaccine development has been followed with unprecedented speed. Some of these vaccines have been advanced to human clinical trials. Convalescent plasma therapy is already practiced in many

Open Access Review

Type I Interferons in COVID-19 Pathogenesis

by Enrico Palermo^{1,*}, Daniele Di Carlo¹, Marco Sgarbanti² and John Hiscot¹

¹ Istituto Pasteur Italia—Cenci Bolognini Foundation, Viale Regina Elena 291, 00161 Rome, Italy

² Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy

* Authors to whom correspondence should be addressed.

Academic Editors: Alessandra Soriani and Alessandra Zingoni

Biology 2021, 10(9), 829; <https://doi.org/10.3390/biology10090829>

Received: 2 August 2021 / Revised: 21 August 2021 / Accepted: 23 August 2021 / Published: 26 August 2021

(This article belongs to the Special Issue Type I Interferons: A Double-Edged Sword of Immune Regulation a Progression)

View Full-Text

Download PDF

Browse Figures

Citation Export

Simple Summary


The innate antiviral immune response is essential to limit virus replication at early stages of infection, thus prevent and pathogenesis. Nevertheless, viruses have evolved different strategies to evade innate immune control. In this describe recent findings delineating the relationship between SARS-CoV-2 and type I IFN response in vitro and in current studies using IFN-based therapy for COVID-19 treatment.

Abstract

Among the many activities attributed to the type I interferon (IFN) multigene family, their roles as mediators of the response have emerged as important components of the host response to Severe Acute Respiratory Syndrome C (SARS-CoV-2) infection. Viruses likewise have evolved multiple immune evasion strategies to circumvent the host response and promote virus propagation and dissemination. Therefore, a thorough characterization of host–virus essential to understand SARS-CoV-2 pathogenesis. Here, we summarize the virus-mediated evasion of the IFN γ the viral functions involved, the genetic basis of IFN production in SARS-CoV-2 infection and the progress of clinical designed to utilize type I IFN as a potential therapeutic tool. View Full-Text

Keywords: type I IFNs; innate immunity; SARS-CoV-2; COVID-19

▼ Show Figures



COVID-19 appears to use mutations adaptively, in the service of its survival and expansion. It circumvents the errors accumulated by random amino acid switches that eradicated previous coronaviruses. To date the infectiousness of this pandemic is exponentially increasing, evolving into even more elusive pernicious variants. By apprehending the ACE2 receptors to contaminate human cells, COVID-19 neutralizes our primary anti-inflammatory and anti-fibrotic defences. The body counterattacks by unleashing chemokines, interleukins, leukocytes, TNF, CSF, but COVID-19 has a strategy: First, it overwhelms the innate response, then it manoeuvres to avoid exposure by inhibiting the adaptive mechanisms of viral recognition. Undetected, COVID-19 multiplies, while the immune system is blindly shooting in the dark, ravaging the vital organs of the host that is fatally injured by the cytokine storm. Vaccines' safety and effectiveness is evaluated along with new therapeutics. The focus is on COVID-19 susceptibility factors, hormonal imbalance, elevated glucose and lipids, obesity, and the male gender. Preventive methods designed to empower immunity are explored.

Checkmate by a Protean Invisible Enemy



Xanya Sofra

Checkmate by a Protean Invisible Enemy

COVID-19: The Danger Within



Dr. Xanya Sofra, Ph.D Neurophysiology, UK / Ph.D Clinical Psy NYC, USA. She is an award-winning international speaker, author of several scientific articles, and the inventor of anti-inflammatory nanotechnology for fitness and bio-repair. Her research explores cellular networks, and the dynamics of molecular mechanisms involved in time reversal.



虚拟健身房用脂肪换肌肉——
——因此 COVID-19 传播的机会更少。虚拟健身房可增强免疫系统，从而更好地对抗 COVID-19



脂肪肝




内脏脂肪无法去除
激光或射频



RADIOFREQUENCY
OR ULTRASOUND



LIPOSUCTION





PLASTIC SURGERY



LASERS


脂肪组织来源的间充质干细胞


- 来自脂肪组织的间充质干细胞修复肝脏 MSCs 在脂肪组织中的比例为 100 分之一，而在骨髓中的比例为 100,000 分之一
- 虚拟健身房导致脂肪含量自然释放到血液中。这些包含分化为修复肝脏的间充质干细胞和排毒肝脏的肝细胞的干细胞



Biomedical Research and Therapy

Mesenchymal stem cells accelerate liver regeneration in acute liver failure





非酒精性脂肪 肝 (NAFLD) 的预测因子

- 丙氨酸氨基转移酶 (ALT) 升高——一种在肝脏中发现的酶 / 肝炎检测
- 天冬氨酸氨基转移酶 (AST) 升高——肝损伤的酶检测
- 碱性磷酸酶升高, ALP 酶标志着肝脏、胆囊、骨骼的损伤
- 肌酐升高——肌肉产生的废物
- 甘油三酯升高
- 通过 CRP 测量的炎症增加
- 胰岛素抵抗
- 高葡萄糖 (糖尿病)
- 肥胖
- 代谢综合征

ALT、AST 和 ALP NAFLD 指标升高的症状:

弱点

疲劳

腹部肿胀

肚子痛

食欲改变

皮肤发痒

深色尿液

浅色凳子

水肿（手臂和手指肿胀）

水肿（腿部和脚踝肿胀）

恶心

呕吐

瘀伤

黄疸（皮肤、眼睛和指甲发黄）

Table 1. Blood Test Results on ALT (SGPT), AST (SGOT), ALP and Albumin

ALT Normal Range: 0-32 IU/L

AST Normal Range: 0-40 IU/L

ALP Normal Range: 44-121 IU/L

Albumin Normal Range: 3.8-4.8

Gender Age	Medical History	ALT IU/L		AST IU/L		ALP IU/L		Albumin g/dL	Albumin g/dL
		Pre	Post	Pre	Post	Pre	Post	Pre	Post
F/64	Fatty Liver Prediabetes	28	24	38	31	109	89	3.0	3.9
F/58	Fatty Liver Prediabetes	34	25	39	28	117	92	3.4	4.3
F/59	Fatty Liver Prediabetes	33	26	41	30	114	87	3.1	4.1
F/54	Fatty Liver Prediabetes	36	23	39	29	120	105	3.6	4.2
F/62	Fatty Liver Prediabetes	29	22	41	26	122	112	3.2	4.0
M/54	Fatty Liver Prediabetes	27	19	40	22	119	106	3.3	4.3
M/57	Fatty Liver Prediabetes	32	21	36	24	112	98	3.5	4.0
M/59	Fatty Liver Prediabetes	31	26	38	31	118	102	3.1	3.9
M/60	Fatty Liver Prediabetes	27	22	39	18	121	104	3.7	3.9
M/55	Fatty Liver Prediabetes	33	25	42	29	118	105	3.3	4.0
Mean Total		31	23.3	39.3	26.8	117	100	3.32	4.06
		ALT Average Decrease: -24.83%		AST Average Decrease: -30.407%		ALP Average Decrease: -14.529%		Albumin 白蛋白 Average Increase: +%22.289	
		Value of t= -8.724 The value is p=0.00001 Significance: p<0.0001		Value of t= -8.83 The value is p=0.00001. Significance: p<0.0001		Value of t= -10.8912 The value is p=0.00001. Significance: p<0.0001		Value of t=+9347886 The value is p<0.00001. Significance: p<0.00001	

Table 2. Subjects results on Creatinine and Bilirubin & Ultrasonography Results							
Creatinine Normal Range: 0.5-1.10 mg/dL							
Bilirubin Normal Range: 0.3-1.2 \mg/dL							
Age	Gender/	Medical History	Creatinine Serum PRE mg/dL	Creatinine Serum POST mg/dL	Bilirubin mg/dL PRE	Bilirubin mg/dL POST	Results Ultrasonography
F/64		Prediabetes Fatty Liver	1.35	0.94	1.13	1.09	Significantly Improved Liver
F/58		Prediabetes Fatty Liver	1.23	0.87	1.29	1.18	Normal Liver
F/59		Prediabetes Fatty Liver	1.26	1.05	1.23	1.14	Normal Liver
F/54		Prediabetes Fatty Liver	1.33	0.96	1.75	1.19	Normal Liver
F/62		Prediabetes Fatty Liver	1.25	1.02	1.21	1.15	Significantly Improved Liver
M/54		Prediabetes Fatty Liver	1.13	1.01	1.27	1.19	Normal Liver
M/57		Prediabetes Fatty Liver	1.16	0.82	1.23	1.12	Normal Liver
M/59		Prediabetes Fatty Liver	1.18	0.98	1.41	1.15	Significantly Improved Liver
M/60		Prediabetes Fatty Liver	1.11	0.87	1.22	1.17	Normal Liver
M/55		Prediabetes Fatty Liver	1.96	1.23	1.47	1.20	Normal Liver
MEAN TOTAL			1.22 mg/dL	0.98 mg/dL	1.321 mg/dL		1.158 mg/dL
Mean Average		Creatinine % Decrease		Mean Average Bilirubin % Increase			
-19.67% mg/dL				-12.33% mg/dL			
Value of t=-59420				Value of t=-3.1911			
The value is p=0.00011. Significance: p<0.001				The value is p=0.00549. Significance: p<0.01			

Our Results on Fatty Liver

糖尿病患者治疗后没有脂肪肝




Table 3. TYPE 2 DIABETICS TWENTY VIRTUAL GYM TREATMENTS
Triglycerides, High-Density Protein (HDL),
Presence of Fatty Liver on Sonography Reports Pre and Post Treatment.

Triglycerides Normal Range: > 150 mg/dL;
 High-Density Lipoprotein (HDL) Normal Range: Men >60 mg/dL; Women >60 mg/dL
 High-Density Lipoprotein (HDL) At Risk: Men: < 40 mg/dL; Women < 50 mg/dL

No	Gender	Age	Medical Diagnosis Pre Treatment	Fatty Liver Post on Sonography Reports	Triglycerides mg/dL Pre	Triglycerides mg/dL Post	Triglycerides mg/dL decrease	HDL mg/dL Pre	HDL mg/dL Post	(HDL) mg/d Increase
1	Female	45y	Diabetes	No fatty liver	203	158	Improved (abnormal)	32	39	Improved at risk
2	Female	46y	Diabetes	No fatty liver	287	176	Improved (abnormal)	32	39	Improved at risk
3	Female	48y	Diabetes	No fatty liver	266	147	Normal	29	41	Improved at risk
4	Male	44y	Diabetes	No fatty liver	283	189	Improved (abnormal)	30	35	Improved at risk
5	Female	45y	Diabetes	No fatty liver	225	179	Improved (abnormal)	33	40	Improved at risk
6	Female	47y	Diabetes	No fatty liver	237	188	Improved (abnormal)	31	41	Improved at risk
7	Female	45y	Diabetes	No fatty liver	228	134	Normal	34	58	Normal
8	Female	45y	Diabetes	No fatty liver	214	138	Normal	28	51	Normal
9	Female	68y	Diabetes	No fatty liver	198	122	Normal	31	59	Normal
10	Female	61y	Diabetes	No fatty liver	219	112	Normal	28	52	Normal
11	Male	55y	Diabetes	No fatty liver	223	106	Normal	24	66	Normal
12	Male	69y	Diabetes		215	158	Normal	35	47	Improved at risk
13	Male	46y	Diabetes		230	176	Improved (abnormal)	28	37	Improved at risk
14	Female	52y	Diabetes		196.7	147	Normal	47.6	53	Normal
15	Female	49y	Diabetes		193	189	Normal	34.5	38	Improved at risk
16	Male	45y	Diabetes		212	179	Normal	41	45	Improved at risk
17	Male	72y	Diabetes		197	188	Normal	26	38	Improved at risk
18	Male	59y	Diabetes		202	134	Normal	31	62	Normal
19	Male	49y	Diabetes		197	138	Normal	44	71	Normal
20	Male	57y	Diabetes		192	122	Normal	37	61	Normal
21	Male	55y	Diabetes		199	112	Normal	42	68	Normal
TOTAL					4616.7	3298		698.1	1041	
AVERAGE					219.84	157.04	Improved	33.24	49.57	Improved
% OF TRIGLYCERIDES DECREASE							-28.56%	% OF HDL INCREASE		+49.12%

Table 3. Blood Test Results on TG,VLDL and CRP

TG Normal Range: 0-149 mg/dL

VLDL Normal Range: 5-40 mg/dL

CRP Normal Range: 0-10 mg/L

Gender Age	Medical History	TG mg/dL Pre	TG mg/dL Post	VLDL mg/dL Pre	VLDL mg/dL Post	CRP mg/L Pre	CRP mg/L Post
F/64	Fatty Liver Prediabetes	195	146	45	32	14	9
F/58	Fatty Liver Prediabetes	193	147	43	35	12	7
F/59	Fatty Liver Prediabetes	167	123	41	34	11	8
F/54	Fatty Liver Prediabetes	156	129	38	31	12	9
F/62	Fatty Liver Prediabetes	178	134	48	36	15	10
M/54	Fatty Liver Prediabetes	188	139	40	29	13	8
M/57	Fatty Liver Prediabetes	183	141	42	32	15	9
M/59	Fatty Liver Prediabetes	191	146	37	28	10	7
M/60	Fatty Liver Prediabetes	172	132	39	29	11	8
M/55	Fatty Liver Prediabetes	159	115	43	32	13	9
Mean Average		178.2	135.2	41.6	31.8	12.6	8.4
		TG % decrease: -24.130%		VLDL % decrease: -23.55%		CRP % decrease: -33.333%	
		Value of t=-7.431 The value is p=0.00002. Significance: p<0.0001		Value of t=-9.175 The value is p<0.00001. Significance: p<0.00001		Value of t=-11.698 The value is p<0.00001. Significance: p<0.00001	


**TABLE 5. BLOOD TEST RESULTS ON CORTISOL (F), TESTOSTERONE (T) AND MUSCLE MASS (MM)
 CORTISOL NORMAL RANGE MEN AND WOMEN: 80-477 NMOL/L
 TESTOSTERONE NORMAL RANGE MEN: 10-35 NMOL/L
 TESTOSTERONE NORMAL RANGE WOMEN: 0.5 – 2.4 NMOL/L
 MUSCLE MASS MALE AND FEMALE AGES 54-64: AVERAGE; 33-55 LOW: < 33 HIGH:>55**

Gender Age	Medical History	Cortisol Pre	Cortisol Post	T Pre	T Post	MM Pre	MM Post
F/64	Fatty Liver Prediabetes	481	319	0.4	1.27	24	36
F/58	Fatty Liver Prediabetes	455	247	0.6	1.26	29	38
F/59	Fatty Liver Prediabetes	462	325	0.5	1.38	26	40
F/54	Fatty Liver Prediabetes	449	354	0.8	1.44	25	39
F/62	Fatty Liver Prediabetes	396	286	0.7	1.22	23	42
M/54	Fatty Liver Prediabetes	476	368	11.99	18.54	29	49
M/57	Fatty Liver Prediabetes	451	312	12.89	19.33	30	51
M/59	Fatty Liver Prediabetes	479	347	11.92	17.62	29	46
M/60	Fatty Liver Prediabetes	478	366	12.12	17.57	26	38
M/55	Fatty Liver Prediabetes	429	325	14.7	20.33	31	52
Mean Average		455.6	324.9	6.36	9.996	27.2	43.1
		Cortisol % decrease: -28.687%		Testosterone % INCREASE: +50.04%		Muscle Mass % INCREASE: +58.45%	
		Value of t=-14.01212.190 The value is p<0.00001 Significance: p<0.00001		Value of t=+3.786 The value is p=0.00215 Significance: p<0.01		Value of t=+11.746 The value is p<0.00001 Significance: p<0.00001	


TABLE 4. BMI, BMR AND VAT
BMI NORMAL RANGE MEN (DEPENDING ON WEIGHT AND HEIGHT): 1-24
BMI NORMAL RANGE WOMEN (DEPENDING ON WEIGHT AND HEIGHT): 1-23
BMR NORMAL RANGE MEN: 1600-1800 CAL/ PER DAY.
BMR NORMAL RANGE WOMEN: 1550. CAL/PER DAY
VAT (RANGES FROM 1-59) NORMAL RANGE: 1-12

Gender Age	Medical History	BMI Pre	BMI Post	BMR Pre	BMR Post	VAT Pre	VAT Post
F/64	Fatty Liver Prediabetes	34.2	26.5	920	1490	39	27
F/58	Fatty Liver Prediabetes	33.5	25.9	1005	1510	33	21
F/59	Fatty Liver Prediabetes	30.4	24.7	1156	1499	51	32
F/54	Fatty Liver Prediabetes	32.3	26.6	1098	1620	39	23
F/62	Fatty Liver Prediabetes	30.8	24.9	953	1457	42	29
M/54	Fatty Liver Prediabetes	31.6	25.7	1167	1663	48	31
M/57	Fatty Liver Prediabetes	31.1	24.8	1249	1833	35	26
M/59	Fatty Liver Prediabetes	32.4	27.4	1055	1692	39	28
M/60	Fatty Liver Prediabetes	31.2	26.3	1012	1757	41	27
M/55	Fatty Liver Prediabetes	32.4	25.3	1179	1633	43	29
Mean Average		31.9	25.81	1079.4	1615.4	41	27.3
		BMI % decrease: -19.09%		BMR% INCREASE: +49.650%		VAT % decrease: -33.41%	
		Value of t=-14.012		Value of t=+15.685		Value of t=-12.064	
		The value is p<0.00001. Significance: p<0.00001		The value is p<0.00001 Significance: p<0.00001		The value is p<0.00001 Significance: p<0.00001	


间充质干细胞分化成肝细胞，为肝脏解毒



*Hepatocytes are involved in Liver Detox



内脏肥胖的毒性增加了饥饿感



内脏肥胖固有的毒性、超载和损害肝脏解毒系统、促进胰岛素和瘦素抵抗/增加胃饥饿素（食欲的中枢刺激物之一），最终促进饥饿感增加





ONE TREATMENT

排毒和炎症 减少

CLINICAL STUDY

Virtual Gym

Detox – A very Important Function


**The More Toxic you are
The More Hungry you are**

你越毒你就越饿

荷尔蒙失调

毒性

饥饿



Did you know
that toxicity is
one of the
main causes
of weight
gain?

体重增
加


消耗 食物



LEPTIN & GHRELIN IMBALANCE = HUNGER

Ghrelin Leptin
Hunger


Ghrelin Leptin
Satiety



BEFORE EATING



AFTER EATING



食欲激素。瘦素增加，生长素释放肽减少

Table 6. Blood Plasma Results on Leptin and Ghrelin for each subject.

Gender	Age	Ethnicity	Leptin pre ng/mL	Leptin post ng/mL	Normal range ng/mL	% increase ng/mL	Ghrelin pre pg/mL	Ghrelin post pg/mL	Normal range pg/mL	% decrease pg/mL
Male	36	Asian	3.69	3.98	1.2 - 9.5	7.86%	687	602	520 - 700	12.37%
Male	39	Caucasian	4.43	4.98	1.2 - 9.5	9.78%	695	634	520 - 700	8.77%
Male	43	Caucasian	5.62	6.22	1.2 - 9.5	10.68%	598	552	520 - 700	7.69%
Male	35	Asian	6.15	6.83	1.2 - 9.5	11.05%	629	587	520 - 700	6.68%
Female	42	Asian	9.16	9.74	4.1 - 25.0	6.33%	577	542	520 - 700	6.06%
Female	45	Indian	5.23	6.09	4.1 - 25.0	16.44%	659	613	520 - 700	6.99%
Female	49	Caucasian	7.22	8.17	4.1 - 25.0	13.15%	644	617	520 - 700	4.19%
Female	38	Caucasian	12.34	13.22	4.1 - 25.0	7.13%	569	536	520 - 700	5.79%
Female	37	Asian	11.38	13.08	4.1 - 25.0	14.93%	499	461	520 - 700	7.62%
Mean Average Leptin Increase						+10.82%	Mean Average Ghrelin Decrease			-7.35%

There was an inverse relationship between leptin and ghrelin where leptin significantly increased and ghrelin significantly decreased within the normal range. Mean average percentage leptin increase was +10.82% and ghrelin decrease was -7.35%.

SLIMMING VS FITNESS

Lasers / RF Slimming

- Do NOT increase Metabolism
- Do NOT balance Hormones
- Do NOT decrease Hunger

Results Rebound



FITNESS

- Increases Metabolism
- Balances Hormones
- Reduces Hunger

NO Rebound







ONE TREATMENT



ONE
TREATMENT







19 SUBJECTS: TREATMENT 1

TREATMENT 6

为什么你不需要 心血管锻炼 与虚拟健身房

通常，您使用心血管锻炼来增加心率。这些增加了使心脏紧张的心脏的泵送率——对老人有害！虚拟健身房将红细胞分开。您不必增加心脏泵血的速度，因为血液流动时心脏不会因过度泵血而紧张




19
SUBJECTS

	Erythrocyte Aggregation	Rouleau	Fungal Forms	Thrombocyte Aggregation	Bacteria	Poikilocytosis	Rouleau & Separate RBCs	Only Separate RBCs
Before Treatment	15	4	8	8	9	8	0	0
After First Treatment	1	6	6	7	8	6	9	3
Before Last Treatment	0	0	3	4	5	2	11	8
After Last Treatment	0	0	2	2	2	0	3	16

虚拟健身房治疗分离红细胞 (RBC) 氧气

对细胞 细胞营养 作用位点抗体 增强免疫

力 携带废物到肝脏和肾脏排毒






**VIRTUAL
GYM**



**HOW DOES
IT WORK?**


Motor Nerve Blueprint Signals enter the body



Blueprint Motor Nerve
Signal Unlimited Resolution
/ 经过 42 年的研究, 由多
达 8000 个波形组成 电压
驱动皮肤


与运动神经
产生共鸣

觉醒的中枢神经系统通过感
觉神经将信号传送到大脑



传入神经携带信号 通过脊髓到达大脑

Sensory
neurone



荷尔蒙自然触发脂肪含量释
放到血液中

瘦素和 Ghrelin 平衡 = 减少
饥饿感

脂肪组织含有干
细胞

间充质干细胞修复肝
脏和其他重要器官

葡萄糖在线粒体中与
氧气一起燃烧


ATP 生产 = 能量

8-10 秒的大型协调肌肉收缩,
涉及到整个身体, 就像在常
规的剧烈运动中一样

红细胞的分离/淋巴刺激=排毒

Motor nerve fibre

Effector (muscle)



虚拟健身房如何促进健康

1. 无限分辨率复合信号，由多达 8,000 个波形编排而成 收缩是由大脑引起的——大脑命令运动神经收缩身体/全身8-10次收缩 大脑会释放荷尔蒙（就像在常规剧烈运动中一样/但在高速下！） 通过激素将脂肪自然释放到血液中，可维持干细胞的完整性以修复肝脏和其他器官（见于 CRP、胆红素和肌酐正常化） 荷尔蒙释放导致荷尔蒙平衡 荷尔蒙平衡：生长因子/新陈代谢/睾酮增加/皮质醇减少 Leptin / Ghrelin 平衡 = 抑制过度饥饿 红细胞的分离/淋巴系统刺激=排毒=减少渴望 内脏脂肪减少 / 皮下脂肪减少 / BMI 减少 / VLDL 和甘油三酯减少 增加肌肉质量/健身

OPTIMAL CHOLESTEROL

	Mean	$S^2 = SS/df$	T-Value	p-Value	Probability	Comments
VLDL 25 HA / 20 PMD	-1.19	0.31	-9.35	<0.00001	P<0.00001	VLDL was reduced by -41.59%
Triglycerides 25 HA / 40 PMD	-1.25	0.61	-6.94	<0.00001	P<0.00001	Triglycerides were reduced by -31.96%
HDL 30 PMD	9.34	23.66	10.52	<0.00001	P<0.00001	HDL was increased by +19%

METABOLISM INCREASE = RESULTS DO NOT REBOUND

Free T-3 45 HA / 10 PMD	0.93	0.13	11.62	<0.00001	P<0.00001	Free T3 was increased by +41.07% WNR
----------------------------	------	------	-------	----------	-----------	--------------------------------------

BODY SCULPTING

VISCERAL FAT, OVERALL FAT, BMI DECREASE

FITNESS INCREASE

BMR, SMM, IGF-1 INCREASE

VAT 35 HA / 60 PMD	-4.68	7.12	-13.6	<0.00001	P<0.00001	VAT decreased by -21.95%
Overall Fat 50 PMD	-4.98	6.43	-13.88	<0.00001	P<0.00001	Overall Fat decreased by -13.42%
BMI 60 PMD	-2.3	1.28	-15.73	<0.00001	P<0.00001	BMI decreased by -10%
BMR 10 HA	91.6	3782.04	4.71	0.00055	P<0.001	BMR increased by +91.60%
SMM 35 HA / 15 PMD	+4.3	0.45	+13.49	<0.00001	P<0.00001	SMM increased by +40.7%
IGF-1 35 HA				<0.00001	P<0.00001	IGF-1 increased by +19.68

BMR: BASAL METABOLIC RATE: BODY BURNS MORE CALORIES WHILE YOU ARE SLEEPING / TURN CLOCK BACK TO YOUTH

Albumin
Average Increase: +%22.289

Value of t=+9347886
The value is p<0.00001.
Significance: p<0.00001

NO FATTY LIVER

LIVER REPAIR DUE TO:

1. SIGNIFICANT VISCERAL FAT REDUCTION
2. LIVER REPAIR BY THE ADIPOSE TISSUE STEM CELLS – MSCs & HEPATOCYTES

ALT Average Decrease: -24.83% (p<0.001)	AST Average Decrease: -30.407 (p<0.0001)	ALP Average Decrease: -14.529 (p<0.01)
--	---	---

Creatinine 10 PMD	-0.24	0.04	-4.06	0.00143	P<0.01	Creatinine decreased by - 19.67% WNR
CRP 10 PMD	-0.59	0.16	-4.72	0.00055	P<0.001	CRP decreased by -36.87% WNR

Diabetes

Blood Glucose Fasting 15 D	-61.88	7675.12	-8.11	<0.00001	P<0.00001	50% normal after 12 treatments
Blood Glucose PP 15 D	-63.07	7353.79	-845	<0.00001	P<0.00001	33% normal after 12 treatments

Prediabetes

Insulin Fasting 20 PD	-30.71	5961.47	-2.97	0.01031	P<0.01	100% normal after 12 treatments
Insulin PP 20 PD	-129.43	18065.62	-7.20	0.00009	P<0.0001	100% normal after 12 treatments

STRESS REDUCTION


ENERGY INCREASE / FAT REDUCTION

Cortisol 35 HA	-18.26	142.98	-6.66	<0.00001	P<0.00001	Cortisol decreased by -13.08% WNR
Testosterone 35 HA	2.9	4.6	6.05	<0.00001	P<0.00001	Testosterone increased by +43% WNR

HUNGER REDUCTION / NO CRAVINGS = RESULTS DO NOT REBOUND

Leptin 10 HA / 10 PMD	1.82	2.68	4.98	0.00004	P<0.0001	Leptin increased by +13.41% WNR
Ghrelin	-43.55	962.79	-6.28	<0.00001	P<0.00001	Ghrelin decreased

虚拟健身房 8888 FITNESS MAX 提供 256 次锻炼，在一小时内重复 1000 次，总共 25,600 次锻炼。这些包括



力量训练（收缩时间设置为 10 / 休息时间 2）

锻炼（收缩时间设置为 10 / 休息时间 2）

伸展运动（收缩时间设置为 10 / 休息时间 2）

有氧运动 / 跳跃 / 跑步（收缩时间设置为 2 / 休息时间 2）

缓解背痛的运动（收缩时间设置） 开 10 / 休息时间 2）



THE SUNDAY TIMES

INNOVATION 3-11



Keeping trim without the effort of exercise: the Arasys units, already used in beauty salons, could be put to work in hospitals to tone the muscles of bedridden patients

Fighting the flab without sweat

A SCIENTIST has invented a machine he claims will keep people trim without the need for exercise and could help reverse muscle-wasting conditions such as multiple sclerosis, writes Sean Hargrave.

The Arasys exerciser unit (ARADic SYSTEM), developed at London's South Bank University Technopark, is already being sold to health clubs and beauty salons for those who want to lose weight without putting in the effort.

Now the machine's designer, Gerry Pollock, is searching for hospitals and clinics that could help him test the system on disabled patients who are unable to exercise. He believes Arasys could prevent the muscle wastage common among those confined to bed or a wheelchair.

The machine flexes muscle by passing tiny electric currents through nerve endings at either end of muscle

groups. This makes the tissue contract for two seconds, as if it were being put through a gym workout.

A typical session with the machine lasts 17 minutes. Pollock says this is because people can feel tired if they have a longer stint and do not notice as much benefit as from a shorter session. He claims each treatment is the equivalent of doing 300 sit-ups and that three sessions are all that are needed until weight loss can be measured.

The Arasys system can treat four sets of muscle simultaneously. In cosmetic use these are normally the stomach, bottom, thighs and calves. In medical use, this would change to exercise the parts of the body a patient cannot move.

Pollock, a chemist, claims his technology is superior to machines that make similar claims of effortless

weight-loss because of the electric wave form he designed. He says his electronics expertise, that was used in the development of the first pacemaker, ensures the muscles are exercised at the correct speed for the optimum duration.

This involves controlling electrical impulse to avoid suddenly jerky muscle movements. To achieve this, Arasys generates smooth rather than spiked electrical signals so that the muscle is stretched in a manner more similar to way it behaves during real exercise.

"We only discovered how long and intense the signal should be through trial and error during the system's five-year development," says Pollock. "Just passing any old electrical signal across a muscle simply doesn't work."

Besides helping the disabled, Pollock believes his machine could be used to return strength to the elderly

and those who suffer from multiple sclerosis.

His niece, Angela Sylvester, a qualified nurse, regularly uses Arasys on four ME sufferers who are unable to exercise. She claims they all report they feel stronger.

"One of the ladies used to be a fitness instructor, but because of her condition she cannot work out any more," says Sylvester. "she benefits from being able to stay trim and exercise muscles that would otherwise be hardly used."

Pollock hopes his invention will soon be put to its original healthcare use and is keen to talk with clinics and hospitals that believe they could help him tailor the system for individual conditions.

"I need to talk with experts so that we can decide if the present electrical signal is appropriate or if it needs changing," he says.

第一起搏器的共同发明者格里波洛克博士在伦敦大学

英国《星期日泰晤士报》等刊物发表了多篇关于 Gerry Pollock 在伦敦大学的 SIMULATED EFFORTLESS EXERCISE 发明的文章。Pollock 博士对这项发明进行了 27 年的实验室实证（试错）研究。

Gerry Pollock 博士的伦敦大学研究 (1990)

Goldpink 的基因表达研究

❖ 快速肌肉肥大 肌肉的 RNA 含量增加 250% 抑制快速型基因和激活骨骼慢型基因。

Stretch and force generation induce rapid hypertrophy and myosin isoform gene switching in adult skeletal muscle

Geoffrey Goldpink, Andrew Scutt, Jane Martindale, Thomas Jaenicke, Lucien Turay and Gerald-F. Gerlach
Unit of Molecular and Cellular Biology, The Royal Veterinary College, London University, Royal College Street,
London NW1 0TU, U.K.

Summary

Using electrical stimulation to control force generation and limb immobilization to alter the degree of stretch, we have studied the role of mechanical activity in inducing hypertrophy and in determining fast and slow muscle fibre phenotype. Changes in gene expression were detected by analysing the RNA in hybridization studies employing cDNA probes specific for fast and slow myosin heavy chains and other genes. As a result of overload in the stretched position, the fast contracting tibialis anterior muscle in an adult rabbit is induced to synthesize much new protein and to grow by as much as 30% within a period as short as 4 days. This very rapid hypertrophy was found to be associated with an increase of up to 250% in the RNA content of the muscles and an abrupt change in the species of RNA produced. Both stretch alone and electrical stimulation alone caused repression of the fast-type genes and activation of the slow-type genes. It appears that the fast-type IIB genes are the default genes, but that the skeletal slow genes are expressed as a response to overload and stretch. These findings have implications as far as athletic training and rehabilitation are concerned.

Introduction

Muscle is a tissue in which gene expression is regulated to a large extent by mechanical signals. Mammalian muscle consists of populations of slow-contracting, oxidative fibres and fast-contracting fibres which are characterized by different protein isoforms. Therefore, post-natal growth and the differentiation into the fast type or the slow type of fibres must presumably involve the regulation of expression of different subsets of genes. Here we have focused on the expression of myosin heavy chain genes and their response to mechanical stimuli.

The intrinsic velocity of contraction (V_{max}) of muscle fibres is related to the specific activity of their myosin ATPase [1]. Myosin is a double molecule that consists of two heavy chains each of about 220 kDa. The actin-attachment site and the ATPase site are located in the S1 region (head of the myosin

molecule) of each heavy chain. Associated with the S1 fragment are smaller polypeptides called light chains which are believed to modulate the cross-bridge ATPase activity [2]. Subtypes of fast muscle fibre have been identified histochemically and these may exist because of different combinations of myosin heavy and light chains and different mitochondrial content. Slow fibres differ in several ways from fast fibres in that they have many more mitochondria, different cytoplasmic isoenzymes, as well as different isoforms of myofibrillar proteins. The isoforms of myosin have been shown to be the product of a multigene family and their expression is tightly regulated in a stage-specific and tissue-specific manner [3, 4]. Phenotypic expression of muscle genes is known to be influenced by thyroid hormone [5, 6] and altered patterns of innervation [7]. However, the influence of physical activity at the gene level was unclear. We have, therefore, studied changes in transcriptional levels of the fast and slow myosin heavy chain genes in response to stretch and force generation.

Methods

Stimulation and acute-stretch procedures

Tibialis anterior (TA) muscles in adult Netherland dwarf rabbits were stimulated using Teflon-coated stainless-steel electrode wires implanted into the popliteal fossa [8] under valium/Hypnorm anaesthesia. The electrode wires were externalized at the back of the neck and attached to a miniature stimulation circuit which was held in position by a small saddle fashioned out of an elastic bandage. Several circuit designs were used which generated biphasic pulses at frequencies ranging from 2 Hz continuous to 120 Hz intermittent. A 30 Hz intermittent circuit was designed to give the same number of pulses/min as a 2 Hz continuous, and a 120 Hz and 60 Hz intermittent circuit gave the same number of pulses/min as a 10 Hz continuous circuit. In this way, the hypothesis that it is the number of pulses delivered which determines muscle fibre phenotype could be tested. The pulse length was 0.1 ms and the pulse amplitude was adjustable from 1 to 3 V and each miniature stimulator was fitted with an on/off switch. Muscle



amazon.com

Machines - Google Sheets

(99+) Mike Barnicle | Lin...

Unable to Follow-Up wit...

All Xanya Sofra

Gain Gift Cards Polyxen's Amazon.com Customer Service Browsing History Registry

RESULTS

Price and other details may vary based on product size and color.



How Narcissism Invented Trumpism
The Sadosomasochistic Amphisbaena



How Narcissism Invented Trumpism: The Sadosomasochistic Amphisbaena

by Xanya Sofra

Paperback
\$72.00

FREE Shipping to Hong Kong

More Buying Choices
\$71.80 (2 new offers)



Checkmate by a Protean Invisible Enemy
COVID-19: The Danger Within



Checkmate by a Protean Invisible Enemy: COVID-19: The Danger Within

by Xanya Sofra

Paperback
\$68.00

FREE Shipping to Hong Kong

More Buying Choices
\$67.80 (2 new offers)



morebooks.de

Machines - Google Sheets

(99+) Brian Stelter | Link...

Search results for "xanya...

Amazon.com : Xanya So...

GOP Cowards Afraid To...

LOGIN

0 products in the shopping cart

Searchphrase

English

EUR (€)

Total: 0.00 €



Yes i want More Books!



Categories

- > Fiction
- > Children and Youth books
- > Humanities, Art, Music
- > Natural-, Medical-, Computer Sciences, Technology
- > Social sciences, law, economics
- > School and learning
- > Specialized book
- > Travel
- > Councillor
- > Other

Search results for xanya sofra

Hits: 8

Results per page 15 Change Refine Search



Checkmate by a Protean Invisible Enemy
COVID-19: The Danger Within
Medicine
LAP LAMBERT Academic Publishing (2021-08-04) - ISBN-13: 978-620-4-18285-8

57.90 €



How Narcissism Invented Trumpism
The Sadosomasochistic Amphisbaena
Clinical disciplines
LAP LAMBERT Academic Publishing (2022-04-11) - ISBN-13: 978-613-7-42416-2

65.90 €



Xanya Sofra



Dr. Xanya Sofra, M.D. Neurophysiology (UK), Ph.D. Clinical Psy (USA), MD, is an award-winning international speaker, author of several scientific articles, and the creator of anti-inflammatory neurophysiology for "Stress and Sleep". Her research explores cellular mechanisms, and the dynamics of neuronal mechanisms related to time reversal.



Checkmate by a Protean Invisible Enemy

COVID-19: The Danger Within



Xanya Sofra



Professor Xanya Sofra, Ph.D. is the author of "Checkmate by a Protean Invisible Enemy", 27 research / scientific papers, articles, and an award-winning international speaker. She has delivered in Neurophysiology and Clinical Psychology. She is the founder of neurophysiology and the founder of neurophysiology and the founder of neurophysiology and the founder of neurophysiology.



How Narcissism Invented Trumpism

The Sadosomasochistic Amphisbaena



amazon.com

Xanya Sofra - Goog... Customers Sofra: A Review of... Need to order the L...

7 results for "xanya sofra"

Free Shipping by Amazon
 Eligible for Free Shipping

Department
 Any Department
 Books
 Arts & Photography
 Biographies
 Business & Money
 Calendars
 Children's Books
 Christian Books & Bibles
 Comics & Graphic Novels
 Computers & Technology
 Cookbooks, Food & Wine
 Crafts, Hobbies & Home
 Education & Teaching
 Engineering & Transportation
 Health, Fitness & Dieting
 History
 Humor & Entertainment
 Law
 LGBTQ+ Books
 Literature & Fiction
 Medical Books
 Mystery, Thriller & Suspense
 Parenting & Relationships
 Politics & Social Sciences
 Reference
 Religion & Spirituality
 Romance
 Science & Math
 Science Fiction & Fantasy
 Self-Help
 Sports & Outdoors
 Teen & Young Adult Books
 Text Preparation
 Travel

Format
 Paperback


Language
 Spanish


New Releases
 Last 30 days
 Last 90 days


Condition
 New


Availability
 Include Out of Stock


RESULTS
 Price and other details may vary based on product size and color.



 Checkmate by a Protean Invisible Enemy: COVID-19: The Danger Within
 by Xanya Sofra | Aug 4, 2021
Paperback
 \$68.00
FREE Shipping to Hong Kong
 More Buying Choices
 \$67.80 (\$ new offers)


 How Narcissism Invented Trumpism: The Sodomasochistic Amphibaena
 by Xanya Sofra | Apr 11, 2022
Paperback
 \$72.00
FREE Shipping to Hong Kong
 More Buying Choices
 \$71.80 (\$ new offers)


 Echec et mat par un ennemi invisible protéiforme: COVID-19 : Le danger intérieur (French Edition)
 French Edition | by Xanya Sofra | Jul 8, 2022
Paperback
 \$59.00
FREE Shipping to Hong Kong


 Xaque-mate por um Inimigo Invisível Protean: COVID-19: O Perigo Dentro (Portuguese Edition)
 Portuguese Edition | by Xanya Sofra | Jul 8, 2022
Paperback
 \$59.00
FREE Shipping to Hong Kong


 Scacco matto da parte di un nemico invisibile e proteiforme: COVID-19: il pericolo interiore (Italian Edition)
 Italian Edition | by Xanya Sofra | Jul 8, 2022
Paperback
 \$59.00
FREE Shipping to Hong Kong


 Jaque mate por un enemigo invisible proteico: COVID-19: El peligro interior (Spanish Edition)
 Spanish Edition | by Xanya Sofra | Jul 8, 2022
Paperback
 \$59.00

amazon reload
 Add funds to track your spending
 Learn more >

Sponsored

morebooks.de

Treatment of N... Xanya Sofra - ... Customers Sofra: A Review of... Need to order... Respond to lea... Scacco matto... Search results...

Install 中文 Deutsch

More Books! i want MoreBooks!

Search results for Xanya Sofra

Hits: 14 Results per page 15 Change Refine Search

Categories

- > Fiction
- > Children and Youth books
- > Humanities, Art, Music
- > Natural-, Medical-, Computer Sciences, Technology
- > Social sciences, law, economics
- > School and learning
- > Specialized book
- > Travel
- > Councillor
- > Other

Links

- > Publisher's overview
- > Group Deals
- > Bestsellers
- > Our Distributors

Become Author with OMNIScriptum

PUBLISH NOW!

DISCOVER Amazon.com VISA MasterCard PayPal

Schachmatt durch einen unsichtbaren Protean-Felnd COVID-19: Die innere Gefahr **Medicine**
 Verlag Unser Wissen (2022-07-08) - ISBN-13: 978-620-4-93530-0
 NEW 57.90 €

Scacco matto da parte di un nemico invisibile e proteiforme COVID-19: Il pericolo interiore **Medicine**
 Edizioni Sapientia (2022-07-08) - ISBN-13: 978-620-4-93532-4
 NEW 57.90 €

Jaque mate por un enemigo invisible proteico COVID-19: El peligro interior **Medicine**
 Ediciones Nuestro Conocimiento (2022-07-08) - ISBN-13: 978-620-4-93531-7
 NEW 57.90 €

Checkmate by a Protean Invisible Enemy COVID-19: The Danger Within **Medicine**
 LAP LAMBERT Academic Publishing (2021-08-04) - ISBN-13: 978-620-4-18285-8
 57.90 €

How Narcissism Invented Trumpism The Sodomasochistic Amphibaena **Clinical disciplines**
 LAP LAMBERT Academic Publishing (2022-04-11) - ISBN-13: 978-613-7-42416-2
 65.90 €

Échec et mat par un ennemi invisible protéiforme COVID-19 : Le danger intérieur **Medicine**
 Editions Notre Savoir (2022-07-08) - ISBN-13: 978-620-4-93541-6
 NEW 57.90 €

Scacco matto da parte di un nemico invisibile e proteiforme COVID-19: il pericolo interiore **Medicine**
 Novas Edições Académicas (2016-03-23) - ISBN-13: 978-3-330-72869-1
 35.90 €

Xaque-mate por um inimigo invisível Protean COVID-19: O Perigo Dentro **Medicine**
 Edições Nosso Conhecimento (2022-07-08) - ISBN-13: 978-620-4-93533-1
 NEW 57.90 €

Impacto da doença falciforme no cuidador Qualidade de vida relacionada à saúde de cuidadores de crianças e adolescentes To the book Impacto da doença falciforme no cuidador with isbn 978-3-330-72869-1
 Novas Edições Académicas (2016-03-23) - ISBN-13: 978-3-330-72869-1
 35.90 €

Scientific Research
An Academic Publisher

OPEN ACCESS Login

Home Articles Journals Books News About Submit

Scientific Research Publishing

Xanya Sofra, Ph.D

Journals A-Z Recently Published Papers OPEN ACCESS More>> Special Issues

- **Dynamics of Female Sexuality; Hidden Emotional Issues**

[Xanya Sofra](#)

[Health Vol.12 No.6](#) , June 29, 2020

DOI: [10.4236/health.2020.126051](https://doi.org/10.4236/health.2020.126051) 145 Downloads 366 Views

- **The Importance of Systemic Balance in Safeguarding Health: A Randomized Double-Blind Clinical Trial on VLDL, Triglycerides, Free T3, Leptin, Ghrelin, Cortisol and Visceral Adipose Tissue**

[Xanya Sofra](#)

[Health Vol.12 No.8](#) , August 28, 2020

DOI: [10.4236/health.2020.128078](https://doi.org/10.4236/health.2020.128078) 228 Downloads 513 Views [Citations](#)

- **The Dark Reflection of Sadism within the Brilliance of the Narcissistic Persona**

[Xanya Sofra](#)

[Health Vol.12 No.9](#) , September 29, 2020

DOI: [10.4236/health.2020.129092](https://doi.org/10.4236/health.2020.129092) 332 Downloads 864 Views

- **Vaccines' Safety and Effectiveness in the Midst of Covid-19 Mutations**

[Xanya Sofra](#)

[Health Vol.13 No.3](#) , March 18, 2021

DOI: [10.4236/health.2021.133023](https://doi.org/10.4236/health.2021.133023) 240 Downloads 606 Views

- **Technological Advances in Accelerated Wound Repair and Regeneration**



Biography: Dr Sofra has a doctorate from in Neurophysiology from City University London, UK, and a doctorate in Clinical Psychology from the New School for Social Research, New York City, USA. She is an award-winning international speaker in several Medical and Anti-aging societies and author of several published research and scientific review articles. She was been in clinical practice for years prior to be involved in the invention of advanced anti-inflammatory nanotechnology designed for wound healing, pain relief and systemic balance. Her current research is on signalling pathways, hormonal interactions, and the investigation of existing biological molecular mechanisms involved in time reversal.

[Xanya Sofra](#), [Nuris Lampe](#)

[Health Vol.12 No.7](#) , July 6, 2020

DOI: [10.4236/health.2020.127053](https://doi.org/10.4236/health.2020.127053) 270 Downloads 854 Views

- **A Randomized Longitudinal Double-Blind Clinical Trial on Long-Term Neuropathic Symptomatology Relief & Pain Analgesia**

[Xanya Sofra](#), [Nuris Lampe](#)

[Health Vol.12 No.7](#) , July 8, 2020

DOI: [10.4236/health.2020.127054](https://doi.org/10.4236/health.2020.127054) 343 Downloads 685 Views

- **Adverse Effects of Sedentary Lifestyles: Inflammation, and High-Glucose Induced Oxidative Stress—A Double Blind Randomized Clinical Trial on Diabetic and Prediabetic Patients**

[Xanya Sofra](#), [Sheetal Badami](#)

[Health Vol.12 No.8](#) , August 19, 2020

DOI: [10.4236/health.2020.128076](https://doi.org/10.4236/health.2020.128076) 372 Downloads 942 Views [Citations](#)



- **ArticleNO ACCESS**

[How to get rid of visceral fat: a randomised double-blind clinical trial](#)

- [Xanya Sofra](#)

[Journal of Aesthetic Nursing Volume 9, Issue 702 Sep 2020](#)

[Abstract](#)

- **ArticleNO ACCESS**

[Gain without pain: beyond sport effortless exercise solutions](#)

- [Xanya Sofra](#)

[Journal of Aesthetic Nursing Volume 9, Issue 502 Jun 2020](#)

[Abstract](#)

- **ArticleNO ACCESS**

[Empowering the woman: a comprehensive model of sexual anti-ageing](#)

- [Xanya Sofra,](#)
- [Nuris Lampe](#)

[Journal of Aesthetic Nursing Volume 9, Issue 302 Apr 2020](#)

[Abstract](#)



We aim to accelerate scientific discoveries in modern scholarly communications through the effective use of editorial and publishing polices

[Read more](#)

[The Affinity between Obesity and COVID-19](#)

Research Article - Journal of Endocrinology and Metabolism Research
Oct 16, 2020

[A Review of COVID19 associated factors: CRP, Creatinine, Bilirubin, VLDL, HDL, Triglycerides, Cortisol and Thyroid Function](#)

Research Article - Journal of Endocrinology and Metabolism Research
Oct 16, 2020

[The War Against SARS-CoV-2: The Immune Giant Collapsing Under Its Own Rampaging Cytokine Storm](#)

Research Article - Journal of Endocrinology and Metabolism Research
Feb 11, 2021

[Covid-19 Mutations and How the Vaccine Enhances Immune Intelligence](#)


Review Article - Journal of Endocrinology and Metabolism Research
Feb 11, 2021

[Female Social Empowerment and the Psychological Expression of Endocrinological Issues during Menopause](#)

Review Article - Journal of Endocrinology and Metabolism Research
Apr 11, 2021



Biography: Dr Sofra has a doctorate from in Neurophysiology from City University London, UK, and a doctorate in Clinical Psychology from the New School for Social Research, New York City, USA. She is an award-winning international speaker in several Medical and Anti-aging societies and author of several published research and scientific review articles. She was been in clinical practice for years prior to be involved in the invention of advanced anti-inflammatory nanotechnology designed for wound healing, pain





Biography: Dr Sofra has a doctorate from in Neurophysiology from City University London, UK, and a doctorate in Clinical Psychology from the New School for Social Research, New York City, USA. She is an award-winning international speaker in several Medical and Anti-aging societies and author of several published research and scientific review articles. She was been in clinical practice for years prior to be involved in the invention of advanced anti-inflammatory nanotechnology designed for wound healing, pain relief and systemic balance. Her current research is on signalling pathways, hormonal interactions, and the investigation of existing biological molecular mechanisms involved in time reversal.



Home About Us Journals Guidelines - Join us - Membership Peer Review System

ACTA SCIENTIFIC GASTROINTESTINAL DISORDERS



Publisher : Acta Scientific
Current Issue : Volume 4 Issue 6 - 2021
ISSN : 2582-1091
Impact Factor : 0.622
Issue Release Date : June 01, 2021
Frequency : Monthly
Language : English
Format : Online
Review : Double Blinded Peer Review
Email : gastro@actascientific.com


Research Article

Exercise Solutions for the Optimal Metabolic Control of Type 2 Diabetes

- [Xanya Sofra, Ph.D](#) and Sheetal Badami
- Published: May 25, 2021; Volume 4 Issue 6: 54-69.

[Google ScholarPDFFull Text](#)

www.actascientific.com/ASGIS-4-6.php



Welcome to Bilingual Publishing Co.



+65 65881289
contact@bipublishing.com

HOME ABOUT LOGIN REGISTER SEARCH



JOURNAL	ISSUE	TITLE	
Journal of Endocrinology Research	Vol 2, No 1 (2020)	The Danger within: Covid-19 Affinity for ACE2 Receptors in Adipose Tissue and Testes. The Protective Effects of Estradiol, Fitness, and Weight Management	ABSTRACT PDF
<i>Xanya Sofra</i>			
Journal of Endocrinology Research	Vol 2, No 1 (2020)	SARS-CoV-2-the Unforeseen Peril of David Winning Against Goliath: the Immune Giant Collapsing Under Its Own Rampaging Cytokine Storm	ABSTRACT PDF
<i>Xanya Sofra</i>			
Journal of Endocrinology Research	Vol 3, No 1 (2021): Online First	Covid-19 Mutations and How the Vaccine Enhances Immune Intelligence	ABSTRACT PDF
<i>Xanya Sofra</i>			

虚拟健身房提高耐力、核心力量和速度


其他 NFL 和欧洲著名体育运动员已购买虚拟健身房供个人使用，以提高耐力、核心力量和速度。他们中的大多数人并没有同意我们透露他们的名字。荷兰足球运动员拉斐尔·蒂莫 (Raphael Timo) 的见证——与克罗夫特一起踢球（右图）：“经过一次虚拟健身房治疗后，健康度提高了 40%！”



有没有不锻炼的锻炼方式？

荷尔蒙与运动相互关联 荷尔蒙触发脂肪燃烧过程以形成维持运动和锻炼肌肉的能量 大脑负责所有运动，包括运动期间的全部肌肉收缩

让我们使用信号来激活运动神经 运动神经（中枢神经系统的一部分）必须涉及大脑，这可能导致全身收缩 大脑将命令必要的激素产生能量，由于负反馈机制，该能量永远不会超过激素平衡 结果：模拟锻炼或不锻炼锻炼



Roman Oben 的见证。
圣地亚哥闪电队/纽约巨人队。Virtual Gym 修复了他的伤势，给了他重新踢球的力量



Effortless Simulated Exercise



8 Seconds Whole Body Contraction



- **ArticleNO ACCESS**

[How to get rid of visceral fat: a randomised double-blind clinical trial](#)

- [Xanya Sofra](#)

[Journal of Aesthetic Nursing](#) Volume 9, Issue 702 Sep 2020

Abstract

- **ArticleNO ACCESS**

[Gain without pain: beyond sport effortless exercise solutions](#)

- [Xanya Sofra](#)

[Journal of Aesthetic Nursing](#) Volume 9, Issue 502 Jun 2020

Abstract

- **ArticleNO ACCESS**

[Empowering the woman: a comprehensive model of sexual anti-ageing](#)


- [Xanya Sofra,](#)
- [Nuris Lampe](#)

[Journal of Aesthetic Nursing](#) Volume 9, Issue 302 Apr 2020

Abstract



ACTA SCIENTIFIC GASTROINTESTINAL DISORDERS



Publisher	: Acta Scientific
Current Issue	: Volume 4 Issue 6 - 2021
ISSN	: 2582-1091
Impact Factor	: 0.622
Issue Release Date	: June 01, 2021
Frequency	: Monthly
Language	: English
Format	: Online
Review	: Double Blinded Peer Review
Email	: gastro@actascientific.com

Research Article

[Exercise Solutions for the Optimal Metabolic Control of Type 2 Diabetes](#)

Scientific Research
An Academic Publisher

Home Articles Journals Books News About Submit

OPEN ACCESS Login

Scientific Research Publishing

Xanya Sofra, Ph.D

Journals A-Z Recently Published Papers OPEN ACCESS More>> Special Issues

- **Dynamics of Female Sexuality; Hidden Emotional Issues**

[Xanya Sofra](#)

[Health Vol.12 No.6](#) , June 29, 2020

DOI: [10.4236/health.2020.126051](https://doi.org/10.4236/health.2020.126051) 145 Downloads 366 Views

- **The Importance of Systemic Balance in Safeguarding Health: A Randomized Double-Blind Clinical Trial on VLDL, Triglycerides, Free T3, Leptin, Ghrelin, Cortisol and Visceral Adipose Tissue**

[Xanya Sofra](#)

[Health Vol.12 No.8](#) , August 28, 2020

DOI: [10.4236/health.2020.128078](https://doi.org/10.4236/health.2020.128078) 228 Downloads 513 Views [Citations](#)

- **The Dark Reflection of Sadism within the Brilliance of the Narcissistic Persona**

[Xanya Sofra](#)

[Health Vol.12 No.9](#) , September 29, 2020

DOI: [10.4236/health.2020.129092](https://doi.org/10.4236/health.2020.129092) 332 Downloads 864 Views

- **Vaccines' Safety and Effectiveness in the Midst of Covid-19 Mutations**

[Xanya Sofra](#)

[Health Vol.13 No.3](#) , March 18, 2021

DOI: [10.4236/health.2021.133023](https://doi.org/10.4236/health.2021.133023) 240 Downloads 606 Views

- **Technological Advances in Accelerated Wound Repair and Regeneration**

[Xanya Sofra](#), [Nuris Lampe](#)

[Health Vol.12 No.7](#) , July 6, 2020

DOI: [10.4236/health.2020.127053](https://doi.org/10.4236/health.2020.127053) 270 Downloads 854 Views

- **A Randomized Longitudinal Double-Blind Clinical Trial on Long-Term Neuropathic Symptomatology Relief & Pain Analgesia**

[Xanya Sofra](#), [Nuris Lampe](#)

[Health Vol.12 No.7](#) , July 8, 2020

DOI: [10.4236/health.2020.127054](https://doi.org/10.4236/health.2020.127054) 343 Downloads 685 Views

- **Adverse Effects of Sedentary Lifestyles: Inflammation, and High-Glucose Induced Oxidative Stress—A Double Blind Randomized Clinical Trial on Diabetic and Prediabetic Patients**

[Xanya Sofra](#), [Sheetal Badami](#)

[Health Vol.12 No.8](#) , August 19, 2020

DOI: [10.4236/health.2020.128076](https://doi.org/10.4236/health.2020.128076) 372 Downloads 942 Views [Citations](#)

We aim to accelerate scientific discoveries in modern scholarly communications through the effective use of editorial and publishing polices

[Read more](#)



[The Affinity between Obesity and COVID-19](#)

Research Article - Journal of Endocrinology and Metabolism Research

Oct 16, 2020

[A Review of COVID19 associated factors: CRP, Creatinine, Bilirubin, VLDL, HDL, Triglycerides, Cortisol and Thyroid Function](#)

Research Article - Journal of Endocrinology and Metabolism Research

Oct 16, 2020

[The War Against SARS-CoV-2: The Immune Giant Collapsing Under Its Own Rampaging Cytokine Storm](#)

Research Article - Journal of Endocrinology and Metabolism Research

Feb 11, 2021

[Covid-19 Mutations and How the Vaccine Enhances Immune Intelligence](#)

Review Article - Journal of Endocrinology and Metabolism Research

Feb 11, 2021

[Female Social Empowerment and the Psychological Expression of Endocrinological Issues during Menopause](#)

Review Article - Journal of Endocrinology and Metabolism Research

Apr 11, 2021



JOURNAL	ISSUE	TITLE	
Journal of Endocrinology Research	Vol 2, No 1 (2020)	The Danger within: Covid-19 Affinity for ACE2 Receptors in Adipose Tissue and Testes. The Protective Effects of Estradiol , Fitness, and Weight Management	ABSTRACT PDF
Xanya Sofra			
Journal of Endocrinology Research	Vol 2, No 1 (2020)	SARS-CoV-2-the Unforeseen Peril of David Winning Against Goliath: the Immune Giant Collapsing Under Its Own Rampaging Cytokine Storm	ABSTRACT PDF
Xanya Sofra			
Journal of Endocrinology Research	Vol 3, No 1 (2021): Online First	Covid-19 Mutations and How the Vaccine Enhances Immune Intelligence	ABSTRACT PDF
Xanya Sofra			

CURRENT RESEARCH PROJECTS BY CLINICIANS



Gerald Pollock, Ph.D
Technology Inventor
London University
Co-inventor of the
First Pacemaker in the
UK. Pioneer in Ultra
Violet Light. EU
Funded Centre BIC



NURIS LAMPE, MD
Dermatologist
Anti-aging Physician
Senior Consultant
EUROPE



DR. SHEETAL BADAMI
M.B.B.S., D.A.
Certified Bariatric
Physician, INDIA




Dr. Lok Ngai Sang
Anti-aging
Physician
Senior Consultant
Hong Kong



THOMAS BARNARD,
MD
Anti-aging Physician
CANADA



HIROYUKI OTOMO
MD, JAPAN
Anti-Aging Doctor
Pain Management




VERONICA YAP
Lymphatic
Disorders
SINGAPORE



XANYA SOFRA, PhD
Specific Waveform
Composition Research and
Development, Ph.D in
Neurophysiology
Ph.D in Clinical Psy
Faculty Member &
International Speaker.



BOB MARSHALL, PhD
Biochemical Research
Energy Specialist, USA



FIONA MAK,
MBChB (Leic)
DPD (Wales),
Anti-aging Physician
General Medicine



**YUKO
KAWAMURA, MD,**
JAPAN
Anti-aging Physician

Diabetic Neuropathy / Pain Relief/
Increased Mobility

Visceral Fat Reduction/ Fatty liver / Increased
Muscle Mass

Hormonal Balance / Metabolism

Hunger / Appetite Control

Lipids and Cholesterol

Inflammation / Oxidative Stress

Increased RBC's separation /Detox / Lymphatic
Drainage

Diabetes - Insulin / Glucose levels

Increased Sexual Drive / Increased Self
Confidence.

Wound Healing

Stretchmarks

Incontinence



I€LLIOS

SCIENCE@IELLIOS.COM



THANK YOU

SCIENCE@IELLIOS.COM